Andre Goy, MD
Promising clinical trial data have highlighted advances in the treatment of mantle cell lymphoma (MCL), but an important next step is applying this progress to routine clinical practice, said Andre Goy, MD.
at the 2018 Pan Pacific Lymphoma Conference, Goy, chief of the Division of Lymphoma, and chairman and director of John Theurer Cancer Center, shared insight on the new array of treatment options for MCL and how to properly implement them.
OncLive: Please provide an overview of your presentation on MCL.
: I am here to share my perspective on MCL and some of the progress we have made. Importantly, we have made significant progress. However, there is a disconnect with what we've seen in clinical trials and in the real world. Overall, in clinical trials, there's been a great endeavor of pushing research in MCL because the outcome with standard therapy is very dismal. If we look at the progression of the last 3 decades in clinical trials of MCL, the median OS went from 2.5 years, or something like that, to 12 or 13 years. Therefore, there has definitely been progress on that front.
... to read the full story